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Abstract
Peroxisome proliferator activated receptors (PPARs) are a family of related receptors implicated
in a diverse array of biological processes. There are 3 main isotypes of PPARs known as PPARα,
PPARβ and PPARγ and each is organized into domains associated with a function such as ligand
binding, activation and DNA binding. PPARs are activated by ligands, which can be both endogenous
such as fatty acids or their derivatives, or synthetic, such as peroxisome proliferators,
hypolipidaemic drugs, anti-inflammatory or insulin-sensitizing drugs. Once activated, PPARs bind to
DNA and regulate gene transcription. The different isotypes differ in their expression patterns,
lending clues on their function. PPARα is expressed mainly in liver whereas PPARγ is expressed in
fat and in some macrophages. Activation of PPARα in rodent liver is associated with peroxisome
proliferation and with suppression of apoptosis and induction of cell proliferation. The mechanism
by which activation of PPARα regulates apoptosis and proliferation is unclear but is likely to involve
target gene transcription. Similarly, PPARγ is involved in the induction of cell growth arrest
occurring during the differentiation process of fibroblasts to adipocytes. However, it has been
implicated in the regulation of cell cycle and cell proliferation in colon cancer models. Less in known
concerning PPARβ but it was identified as a downstream target gene for APC/β-catenin/T cell
factor-4 tumor suppressor pathway, which is involved in the regulation of growth promoting genes
such as c-myc and cyclin D1. Marked species and tissue differences in the expression of PPARs
complicate the extrapolation of pre-clinical data to humans. For example, PPARα ligands such as
the hypolipidaemic fibrates have been used extensively in the clinic over the past 20 years to treat
cardiovascular disease and side effects of clinical fibrate use are rare, despite the observation that
these compounds are rodent carcinogens. Similarly, adverse clinical responses have been seen with
PPARγ ligands that were not predicted by pre-clinical models. Here, we consider the response to
PPAR ligands seen in pre-clinical models of efficacy and safety in the context of human health and
disease.
Introduction
The evaluation of the safety of drugs is a vital but complex
process. Normally, candidate drugs are tested in a range of
in vivo and in vitro pre-clinical models that serve to evalu-
ate genotoxicity, general toxicity, reproductive toxicology
and cardiovascular safety. In vivo studies use both rodent
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and non-rodent animal dosing models depending on the
endpoint and the compound characteristics. Although
such models provide useful information, for some classes
of compounds, the rodent models are poor predictors of
human response, in some cases due to marked species dif-
ferences in expression of the target receptors. For example,
the family of peroxisome proliferator activated receptors
(PPARs) display differences in expression and activation
profiles between rodents and humans making the rodent
models poor predictors of human response. However, this
receptor family is an excellent drug target since the differ-
ent isotypes PPARα, PPARβ and PPARγ play a central role
in coordinating energy balance. Thus, PPARα ligands are
hypolipidaemic and PPARγ ligands are insulin sensitizers
with efficacy in type II diabetes. Here, we consider the re-
sponse to PPAR ligands seen in pre-clinical models of ef-
ficacy and safety in the context of human health and
disease.
Peroxisome proliferator-activated receptors: 
structure, ligands, expression and target genes
Structure
PPARs are ligand-inducible transcription factors that be-
long to the nuclear hormone receptor superfamily, togeth-
er with the receptors for thyroid hormone, retinoids,
steroid hormones and vitamin D. According to the recent-
ly proposed nomenclature of nuclear hormone receptors
[1,2], PPARs form the group C in the subfamily 1 of the
superfamily of nuclear hormone receptors, i.e., NR1C.
PPARs occur in three different isotypes, namely PPARα
(NR1C1), PPARβ (also called PPARδ, NUC-1 or FAAR),
and PPARγ (NR1C3). These receptors have been found in
various species such as cyclostoma [3], teleosts [3], am-
phibians [3], rodents [4] and humans [5–7]. There are
three isoforms of PPARγ [8]; PPARγ1 and PPARγ3 are
identical when fully translated and only differ in their
splice variants, whereas PPARγ2 differs from the other iso-
forms in its N-terminus [9]. The PPAR nomenclature for
PPARβ and PPARγ is a misnomer, since neither of these
PPAR isotypes has been associated with peroxisome
proliferation.
Figure 1
A schematic illustration of the domain structure of PPARs. The most conserved region is C, which consists of a highly con-
served DNA-binding domain. The E/F domain is the ligand-binding domain, which contains the AF2 ligand-dependent activation 
domain. The amino-terminal A/B domain contains the AF1 ligand-independent activation domain. The D domain consists of a 
highly flexible hinge region.
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PPARs are typically organized in main structural and func-
tional domains (Fig. 1): A/B, C, D, and E/F [10,11]:
The amino-terminal A/B region encodes a ligand-inde-
pendent transcriptional activation domain (activation
function-1) that is active in some cell types. The region is
poorly conserved between the three PPAR isotypes. It has
been shown that its phosphorylation state contributes to
the modulation of PPARα and γ activity, by affecting the
receptor/ligand affinity: insulin enhances transcriptional
stimulation by human PPARα via phosphorylation of the
conserved MAP-kinase sites Ser12 and Ser21 in the A/B
domain [12,13], whereas MAP-kinase mediated phospho-
rylation of Ser112 of mouse PPARγ2 lowers transcription-
al activity [14,15].
The ligand binding domain (LBD), or E/F domain of
PPARs, is responsible for ligand-binding and converting
PPARs to an active form that binds DNA and modulates
gene expression. The interaction of PPARs with their lig-
ands, because of the conformational changes that are in-
duced especially involving the transactivation domain
(activation function-2, AF-2) located in the C-terminal α-
helix, allows recruitment of co-activators, such as the ster-
oid receptor coactivator-1 [16,17], the CREB-binding pro-
tein CBP/P300 [18], the tuberous sclerosis gene 2 product
[19], the PPAR binding protein [20], PGC-1 [21], PGC-2
[22], Ara70 [23], and the release of corepressors, such as
the nuclear receptor corepressors (or RXR-interacting pro-
tein 13) and the silencing mediator for retinoid and thy-
roid hormone receptors [18,24,25]. When co-transfected
into cell lines, COUP-TFI [26] and COUP-TFII (also called
ARP-1) [27] block PPAR action by binding specific DNA
sequences in PPAR target genes called peroxisome prolif-
erator responsive elements (PPREs). In addition, the E re-
gion is also important in nuclear localization and
dimerization of the receptor. Indeed, dimerization is es-
sential for the activity of PPARs, as it is for most of the oth-
er members of the nuclear hormone receptor superfamily.
They heterodimerize with 9-cis retinoid X receptor (RXR),
forming a complex that is able to bind, via a central DNA
binding domain (C domain), to PPREs.
The C domain is highly conserved, with its two zinc fin-
ger-like structure and its α-helical DNA binding motifs, as
often found in various transcription factors. The whole
PPRE consensus sequence (TGACCT X TGACCT) fits a
DR1 pattern (DR for direct repeat, 1 for one spacing base
between the two consensus motifs TGACCT) [28]. These
elements bind PPAR-RXR heterodimers with PPAR occu-
pying the 5' extended half site and RXR the 3' half site
[29]. PPAR-RXR heterodimers were shown to compete
with hepatocyte nuclear factor-4 (HNF-4) homodimers
for binding to DR1 elements, resulting in decreases in
transcription of apolipoprotein C-III and transferrin genes
[30,31]. The first PPRE sequences were identified by pro-
moter analysis of the peroxisome proliferator (PP)-re-
sponsive gene, acyl-CoA oxidase (ACO) [32,33]. A
number of studies point to the importance of the sequenc-
es flanking the PPREs for maintaining the optimal confor-
mation of the PPAR-RXR heterodimers on the PPREs
[34,35]. These flanking sequences may provide an extra
level of specificity to different nuclear receptors that recog-
nize the DR1 element [36].
The D region encodes a flexible hinge region, thought to
allow independent movement of the LBD relative to the
DNA binding domain.
PPAR ligands: identification, interaction with PPARs and 
specificity
PPAR ligands can be both synthetic, such as peroxisome
proliferators, hypolipidaemic drugs, anti-inflammatory or
insulin-sensitizing drugs, or endogenous, most of them
being fatty acids or their derivatives.
Among the group of synthetic ligands, fibrates are hypol-
ipidaemic drugs used in the treatment of hyperlipidemia.
Most of them preferentially activate PPARα. Others are in-
dustrial compounds [37]. The insulin-sensitizing thiazoli-
dinedione (TZD) class of compounds is selective for
PPARγ [38], with an affinity (Kds) ranging from 40 nM
(rosiglitazone) to several micromolars (troglitazone).
These two compounds have been approved for the treat-
ment of type II diabetes in humans. They efficiently re-
duce both insulin resistance and triglyceride plasma
levels. Although their main effects are not mediated by
PPARs, some non-steroidal anti-inflammatory drugs, such
as indomethacin, flufenamic acid, ibuprofen or fenopro-
fen, activate both PPARα and PPARγ, which may contrib-
ute to their anti-inflammatory properties [39]. Recently,
the L165041 compound has been identified as being the
first PPARβ-selective synthetic agonist [40].
Fatty acids have been discovered to bind to all three PPAR
isotypes, demonstrating that they are not only energy stor-
ing molecules, but also "hormones" controlling nuclear
receptor activities and consequently gene expression.
Among the three isotypes, PPARα is not only the one that
exhibits a high affinity for fatty acids, but is also the best
characterized in terms of ligand specificity. It has been
shown to have a clear preference for binding of long chain
unsaturated fatty acids, such as the essential fatty acids li-
noleic, linolenic and arachidonic acids, at concentrations
that correlate with circulating blood levels of these fatty
acids. Fatty acid derivatives, such as the inflammatory me-
diators leukotriene B4 and 8(S)-hydroxy-eicosatetraenoic
acid, were also identified as relatively high-affinity ligands
for PPARα [41]. In the case of PPARγ, a metabolite of the
eicosanoid prostaglandin G2, 15-desoxy-∆12,14-PGJ2Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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(15d-PGJ2) is the most potent natural ligand described so
far, with reported Kds varying from 325 nM to 2.5 µM.
Polyunsaturated fatty acids, such as 18:2, 18:3 and 20:4,
seem to be the most efficient PPARβ natural ligands.
Tissue expression distribution
Each of the three PPAR isotypes is expressed in a distinct,
tissue-specific pattern. PPARα is highly expressed in liver,
heart, proximal tubules of kidney cortex, skeletal muscle,
intestinal mucosa and in brown adipose, tissues that are
metabolically very active [42]. PPARγ is most highly ex-
pressed in white and brown adipose tissue, large intestine
and spleen [43,44]. In contrast to PPARα and PPARγ,
which are abundantly expressed in just a few tissues,
PPARβ is expressed in virtually all tissues at comparable
levels [45,46]. Furthermore, there is no sex-specific ex-
pression of the three PPAR isotypes as analyzed in rats
[47].
The fact that some tissues express more than one PPAR
isotype raises the question of PPAR-specific PPRE recogni-
tion. Assessment of the relative DNA-capabilities of the
three PPAR isotypes to 16 native PPREs led to the classifi-
cation of PPREs into three functional groups: strong, in-
termediate and weak elements, which correlates with the
level of PPRE conformity to the consensus element [29].
Surprisingly, the number of identical nucleotides in the
core DR1 region is rather homogeneous across the differ-
ent elements, and it is mainly the number of identities in
the 5'-flanking nucleotides, rather than the stricto sensu
core DR1, which determines the binding strength of a giv-
en PPRE. In all cases, PPARγ binds more strongly than do
PPARα and PPARβ and is thus less dependent on well-
conserved 5'-flanking extension. In contrast, conservation
of the 5'-flank is particularly essential for PPARα binding
and therefore contributes to isotype specificity. The PPAR
DNA-binding activity is also modulated by the isotype of
the RXR heterodimeric partner. Binding of PPAR:RXR to
strong elements is reinforced when RXRγ is the partner,
whereas heterodimerization with RXRα is more favorable
for binding to weak elements.
PPAR target genes
PPARα is a central regulator of hepatic lipid metabolism
as well as participant in genes involved in bile acid synthe-
sis [48]. The first identified PPARα target genes code for
several enzymes involved in the β-oxidation pathway,
namely acyl-CoA oxidase [49], bifunctional enzyme [50]
and thiolase [51]. The activation of long-chain fatty acid
into acyl-CoA thioester by the long-chain fatty acyl-CoA
synthetase is likely to be regulated by PPARα [52].
PPARα also participates in the control of fatty acid trans-
port and uptake, by stimulating the genes encoding the
fatty acid transport protein (FATP), the fatty acid translo-
case (FAT/CD36) and the liver cytosolic fatty acid-binding
protein (L-FABP) (Fig. 2) [53]. The metabolism of triglyc-
eride-rich lipoproteins is modulated by PPARα-depend-
ent stimulation of the lipoprotein lipase gene, which
facilitates the release of fatty acids from lipoprotein parti-
cles, and the down-regulation of apolipoprotein C-III
[54]. Furthermore, PPARα up-regulates apolipoprotein A-
I and A-II in humans, which leads to an increase in plasma
high-density lipoprotein (HDL) cholesterol. Additional
PPARα target genes participate in mitochondrial fatty acid
metabolism [55,56], in ketogenesis [57] and in micro-
somal fatty acid ω-hydroxylation by cytochrome P450 ω-
hydroxylases that belong to the CYP4A family [58,59].
Among the key lipid metabolizing extra-hepatic genes ac-
tivated by PPARα is lipoprotein lipase, involved in the
degradation of triglycerides [60]. Hepatic lipogenesis and
phospholipid transport (MDR2, ABCB4) are regulated by
fibrates [61]. Several bile acid synthetic genes are regulat-
ed by PPARα. Sterol 12α-hydroxylase (CYP8B1), respon-
sible for modulating the cholic acid: chenodeoxycholic
acid ratio, is a PPARα target gene [62]. Interestingly, the
first committed step in bile acid synthesis, CYP7A1, is re-
pressed by PPARα [63,64].
There are also PP-responsive genes that have a link to cell
cycle control although no PPREs have been found in these
genes to date. Induction of the oncogenes c-Ha-ras, jun
and c-myc by PP has been reported and the ability to in-
duce these genes correlates well with tumor-promoting
potential [65–68]. For example, Wy-14,643, clofibrate,
ciprofibrate and DEHP were inducers of c-fos, c-jun, junB
egr-1, and NUP475 whereas the noncarcinogenic PP de-
hydroepiandrosterone was ineffective [67]. In addition,
an immediate early gene (IEG) critically involved in lipid
metabolism, tumor promotion and inflammation, cy-
clooxygenase-2, is also regulated by PP [66]. IEG are key
genes involved in regulating the cell cycle and are charac-
terized by rapid response to mitogens as well as serum and
cycloheximide inducibility [69]. Recently, a novel IEG in-
volved in neuronal differentiation, rZFP-37, was charac-
terized as a PP-regulated gene in rodent liver [70]. These
regulatory genes are critical in the progression of the cell
cycle, particularly the G1 to S transition. For example, PP-
induced expression of growth regulatory genes precedes
entry of the cell in S phase [67]. In addition, alterations in
CDK1, CDK2, CDK4, cyclin D1 and cyclin E have been re-
ported following exposure to PP [67,68,71].
Because expression of PPARγ is highest in adipose tissue,
the search for PPARγ target genes has concentrated on ad-
ipocytes. The two markers of terminal adipocyte differen-
tiation – aP2, a fatty acid-binding protein, and
phosphoenolpyruvate carboxykinase, an enzyme of the
glyceroneogenesis pathway – are indeed regulated by
PPARγ [72]. Similarly, PPARγ also regulates the expressionComparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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of the genes coding for lipoprotein lipase, fatty acid trans-
port protein, and the fatty acid translocase [53]. Recently,
the idea of a link between PPARγ and the insulin signaling
has been reinforced by the finding that the c-Cbl-associat-
ed protein, a signaling protein interacting with the insulin
receptor, could be encoded by a potential PPARγ target
gene [73].
Probably because of its ubiquitous expression, it has been
hard to anticipate a function for PPARβ. However, some
of its target genes have been identified. For example,
PPARβ can promote cellular lipid accumulation in macro-
phages by increasing the expression of genes that are in-
volved in lipid uptake and by repressing key genes
implicated in lipid metabolism and efflux [74].
Regulation of mitosis and apoptosis by PPARs in 
pre-clinical models
PPARα
PPARα ligands such as Wy-14,643, ciprofibrate and clofi-
brate are known to produce peroxisome proliferation and
liver tumors in rats and mice [75,76]. However, since PP
belong to the class of carcinogens whose mode of action
does not involve direct damage to DNA, there have been
several theories to explain how non-mutagenic chemicals
such as PP [77] result in liver cancer. Most notably, the
link between a xenobiotic's ability to alter differentiation,
proliferation and apoptosis with the emergence of tumors
has been well established (Fig. 3) [78]:
Figure 2
PPARα plays a central role in lipid transport and metabolism as well as in the response to xenobiotics. PPARα is since activated 
by a diverse array of ligands, including natural and synthetic compounds. The natural ligands free fatty acids (FFA) originate 
either from the catabolism of chylomicrons (CM), very-low-density lipoproteins (VLDL) or high-density lipoproteins (HDL) via 
the lipoprotein lipase (LPL), or from the degradation of glucose. They are also released in the cell from the fatty acid binding 
protein (FABP). Activated PPARα heterodimerizes with RXR and binds to PPRE to drive expression of target genes.
apoA-I
apoA-II
apoA-III TG
LPL
FFA FABP
RXR PPARα α α α
PPRE
HDL
CM, VLDL
Fibrates
Glucose
Cell membrane
Nucleus
FABP
FATP
FAT/CD36
LPL
apoA -I
apoA- II
Cyp8B1
Cyp4A1Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
Page 6 of 15
(page number not for citation purposes)
Figure 3
The different PPAR isoforms have different functions and activation profiles but share the ability to be activated by natural or 
synthetic ligands. In addition, the activity of PPARα and PPARγ is modulated by phosphorylation providing the opportunity for 
cross-talk between the nuclear hormone receptor and kinase families of regulatory molecules.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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Role of PPARα activation on mitosis
The process of peroxisome proliferation-induced hepato-
carcinogenesis is dependent on PPARα [79]. Mice lacking
this receptor are totally resistant to Wy-14,643-induced
liver tumors [51]. Remarkably, the mice that lack PPARα
do not display the typical pleiotropic response when chal-
lenged with the PP, such as peroxisome proliferation, ab-
normal lipid homeostasis [80] and transcriptional
activation of target genes [51]. Importantly, PPARα-null
mice do not exhibit enhanced cell proliferation as evident
by hepatomegaly, incorporation of bromodeoxyuridine
into DNA, and expression of proteins involved in progres-
sion of the cell cycle, like the proliferating cell nuclear an-
tigen PCNA [71]. These data clearly demonstrate that
PPARα is a key contributor for the process of peroxisome
proliferation, hypertrophy, cell proliferation and hepato-
carcinogenesis. However, even though PPARα regulates
PP-mediated cell proliferation, it is unclear whether this
function is direct or indirect.
PP have mitogenic effects when given directly to primary
hepatocytes in culture [81]. However, others have suggest-
ed that Kupffer cells are responsible for the mitogenic ef-
fects of PP on hepatocytes, presumably via an interleukin
[82] or tumor necrosis factor α (TNFα)-dependent mech-
anism [83]. Kupffer cells represent about 2% of the liver
mass and share many properties with macrophages such
as secretion of the cytokines TNFα, interleukin-1 (IL-1),
IL-2 and IL-6 [84]. In support of the hypothesis that
Kupffer cells are required for the proliferation of hepato-
cytes, Rose et al. [85] showed that inhibition of Kupffer
cell activity by dietary glycine and methylpalmitate inhib-
ited Wy-14,643-induced hepatocyte proliferation. Fur-
thermore, the hepatocyte growth response to PP can be
prevented by antibodies to TNFα [83,86] or TNFα recep-
tor 1 (TNRF1) [87]. More recent studies have revealed that
hepatocytes cultured in the absence of Kupffer cells do not
exhibit cell proliferation when treated with Wy-14,643 or
nafenopin [88,89], and this response can be restored by
returning the Kupffer cells to purified hepatocytes.
In support of the role of TNFα as a key mediator in the
stimulation of hepatocellular proliferation, recent find-
ings suggest that down-regulation of the iron-binding pro-
tein lactoferrin (LF) upon PP treatment may play a role in
initiating the growth response [90]. Indeed, LF may puta-
tively be able to regulate liver expression of TNFα, and
possibly other pro-inflammatory cytokines. Following PP
exposure, the down-regulation of LF expression would re-
sult in increased levels of TNFα, which, in turn, would me-
diate some or all the growth changes associated with PP.
These increased levels would occur by bioactivation or re-
lease of preexisting TNFα protein from hepatic Kupffer
cells rather than by increase in TNFα expression as no
changes in TNFα mRNA levels were detected following PP
treatment [91].
IL-1α was shown to be able to induce DNA synthesis in
mouse hepatocytes, even in the presence of the anti-
TNFR1 antibody, suggesting that IL-1α acts independently
rather than by elaborating TNFα [87]. However, the man-
datory roles of TNFα and interleukins in the regulation of
mitosis in the liver have recently been questioned. Indeed,
mice lacking TNFα [92,93] respond to Wy-14,643 no dif-
ferently than wild-type animals in terms of stimulation of
hepatocyte proliferation. Moreover, cell proliferation can
be still triggered by PP in the liver of IL-6 null transgenic
mice [94,95]. Perhaps multiple cytokines are required to
elicit the mitogenic response to PP. Alternatively, a cy-
tokine that has not yet been characterized might be re-
sponsible for hepatocyte proliferation. Mitogen-activated
protein (MAP) kinase pathways contribute to the trans-
mission of extracellular signals, resulting in the direct or
indirect phosphorylation of transcription factors and sub-
sequent alterations in gene expression [96]. The MEK
(MAP kinase kinase) and extracellular signal regulated ki-
nases (ERK) pathway primarily responds to cellular prolif-
eration signals, while the p38 MAP kinases and c-Jun N-
terminal kinases are modulated by cytokines, growth fac-
tors and a variety of cellular stress signals [97]. Inhibition
of either enzyme in hepatocytes using specific inhibitors
prevented PP-induced increase in S-phase [98], suggesting
a role of MAP kinase activity in PP-regulated cell
proliferation. The activation of both p38 and ERK has
been shown to lead to the release of TNFα and IL-6 by
macrophages and other cell types [99,100]. Therefore, one
of the functions of MAP kinase signaling pathway may be
to regulate the levels of cytokines or interleukines, thereby
controlling cell mitosis in the liver. As mentioned before,
PPARα activation also leads to increase in S-phase. It has
therefore been suggested that PPARα activation would
rely upon p38 MAP kinase-induced phosphorylation
[101]. In support of this assumption, Barger et al. [102]
showed that transcription of PPARα target genes was in-
duced upon PP exposure in a P38 MAP kinase dependent
manner. Moreover, a ligand-independent transcriptional
activation domain in PPARα has been shown to contain
MAP kinase sites [103]. Activation of the MEK-ERK path-
way seems to be a prerequisite for the growth response of
rodent liver cells to PP [65,98,104], suggesting that PP
may be using both stress and growth pathways. Induction
of oxidative stress by PP [85,105] may also play a role in
the activation of MAP kinase pathways. In particular, p38
MAP kinase has been associated with oxidative stress
[106] and has been reported to be constitutively active in
mouse liver [107].Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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Role of PPARα activation on apoptosis
Many PPs such as nafenopin were shown to suppress both
spontaneous apoptosis [108–111] and that induced by di-
verse stimuli including transforming growth factor-β1
(TGFβ1) [112]. The PP-induced suppression of apoptosis
can be reproduced in cultured rodent hepatocytes with
high concentrations of TNFα [83], suggesting that TNFα
may play a role in permitting or mediating such an inhi-
bition. In line with this assumption, removal of TNFα-
producing Kupffer cells from hepatocyte cultures abolish-
es the decrease in apoptosis typically observed with hepa-
tocytes exposed to PPs [88]. Suppression of apoptosis is
restored when the Kupffer cells are added back to the
hepatocyte cultures. Furthermore, in vitro experiments us-
ing a dominant negative repressor of PPARα activity sug-
gested that PPARα mediates the PP-induced suppression
of apoptosis [113]. This was later confirmed in experi-
ments using PP-stimulated hepatocytes from PPARα null
transgenic mice [110,114]. TNFα has been found to be
still capable of suppressing apoptosis in cultured PPARα
null mice in the absence of PPs and PPARα, suggesting
that TNFα is clearly a downstream effector on apoptosis
suppression compared to PPs or PPARα. In the presence
of the protein synthesis inhibitor cycloheximide, the re-
sponse of hepatocytes to TNFα is reversed, with a clear in-
duction of cell death [87]. This finding perhaps explains
the pleiotropic response of rodent liver to TNFα. Depend-
ing on the signaling context, this cytokine may induce or
may suppress hepatocyte apoptosis.
PP-induced suppression of hepatocyte apoptosis was
shown to rely upon the activation of the MEK/ERK signal-
ling pathway [104] as well as the p38 MAP kinase pathway
[115]. The response to PP is also dependent upon the
transcription factor NFκB since a dominant negative form
of the upstream kinase Iκ that activates NFκB prevents the
suppression of apoptosis in response to PP [116].
Recent findings showed that the liver from aged rats is ex-
ceedingly sensitive to the anti-apoptotic effect of PPARα
agonists [117]. This high sensitivity could be related to the
remarkably higher levels of the anti-apoptotic protein Bcl-
2 in aged livers than in livers of young, adult, and middle-
aged animals. Interestingly, the PPARα agonist Wy-
14,643 significantly diminished elements of the pro-ap-
optotic machinery (e.g., Bax, caspases, and fas) in the aged
liver.
In summary, suppression of apoptosis induced by PP may
prevent the removal of damaged or excess cells that would
normally be eliminated, these cells then remaining as tar-
gets for further mitogenic stimulation and DNA muta-
tions [118].
PPARγ
Role of PPARγ activation on mitosis
PPARγ is involved in the induction of cell growth arrest
occurring during the differentiation process of fibroblasts
to adipocytes. Differentiation of 3T3-L1 cells into adi-
pocytes necessitates withdrawal from the cell cycle in ad-
dition to the coexpression of PPARγ and C/EBP, and
involves phosphorylation of the retinoblastoma suscepti-
bility gene product Rb [119]. However, activation of
PPARγ in Rb-/- mouse embryo fibroblasts is sufficient to
induce adipocyte terminal differentiation and thus the
link between PPARγ and Rb phosphorylation remains to
be established [120].
PPARγ ligands may protect the vasculature against injury.
Inhibition of cell growth is among others one mechanism
involved in this process. The antiproliferative effects of
PPARγ ligands on vascular smooth muscle cells are medi-
ated by targeting critical cell cycle regulators, including Rb
and p27Kip1, that regulate the progression of cells from G1
phase into S phase to conduct DNA synthesis [121].
PPARγ ligands have been recently shown to suppress de-
velopment of atherosclerosis in LDL receptor-deficient
mice [122].
Ligand activation of PPARγ results in the inhibition of
proliferation of various cancer cells. Primary human li-
posarcoma cells, which express high levels of PPARγ, can
be stimulated to undergo cell cycle arrest and terminal dif-
ferentiation by treatment with PPARγ and RXR-specific
ligands [123]. Activation of PPARγ also induces a reduc-
tion in growth rate and clonogenic capacity of human
breast cancer cells in culture. In one breast cancer cell line,
which expresses high levels of PPARγ, the resistance to
TZD was associated with a high MAP kinase activity,
which might explain a low PPARγ activity due to phos-
phorylation of the A/B region of the receptor [124].
Human colon tumor cell lines express PPARγ and respond
to diverse PPARγ agonists with a reduced rate of growth
and an increased degree of differentiation. Morphological
maturation, defined by an increased cytoplasmic-to-nu-
clear ratio, was observed concomitantly with changes in
gene expression consistent with a transition to a more dif-
ferentiated state [125]. PPARγ-selective targets included
genes linked to growth regulatory pathways (regenerating
gene IA), colon epithelial cell maturation (GOB-4 and
keratin 20), and immune modulation (neutrophil-gelati-
nase-associated lipocalin) [126]. Drg-1 (differentiation-
related gene-1), a putative suppressor gene in human
colorectal cancer, and PTEN, a tumor suppressor gene
which modulates several cellular functions, including cell
migration, survival, and proliferation, were found to be
controlled at least in part by PPARγ agonists in colon can-
cer cell lines [127,128].Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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Human colorectal carcinoma cells implanted in nude
mice were shown to grow more slowly in mice treated
with troglitazone [125,129]. On the other hand, two inde-
pendent studies performed in mice bearing a mutation in
the adenomatous polyposis coli tumor suppressor gene
(APCmin) showed an increase in tumors or polyps in the
colon after these mice were fed a diet containing a PPARγ
agonist for 8 or 5 weeks [130,131]. The discrepancy with
the above mentioned results obtained with colon cancer
cell lines does not seem to be attributable to the genetic
defect that causes the tumors in mice, since some of these
lines also bear this specific mutation [125,132]. Interest-
ingly, recent studies with mice heterozygous for PPARγ
have shown that heterozygous loss of PPARγ causes an in-
crease in β-catenin levels and a greater incidence of colon
cancer when animals are treated with azoxymethane
[133]. However, mice with preexisting damage to APC, a
regulator of β-catenin, develop tumors in a manner
insensitive to the status of PPARγ. These data show that
PPARγ can suppress β-catenin levels and colon carcino-
genesis but only before damage to the APC/β-catenin
pathway. This finding suggests a potentially important use
for PPARγ ligands as chemopreventative agents in colon
cancer.
Troglitazone showed a potent dose-dependent effect on
the growth inhibition of six hepatocellular carcinoma
(HCC) cell lines [134]. The growth inhibition was linked
to the G1 phase cell cycle arrest through the up-expression
of the cyclin-dependent kinase inhibitors, p21 and p27
proteins, and the hypophosphorylation of retinoblasto-
ma protein. Unfortunately, no PPARγ knock-out transgen-
ic mice are available since deletion of the PPARγ gene in
mice results in embryonic lethality at approximately day
10 of gestation due to placental insufficiency [135].
Role of PPARγ activation on apoptosis
PPARγ ligands have been implicated in inducing apopto-
sis in a number of cell types. For example, rosiglitazone
(at low concentrations, in the range of its Kd value of 20
nM) was able to increase the number of TUNEL-positive
cells and to increase activation of caspase-3 in human
monocyte-derived macrophages [136]. Similarly, TZDs
triggered apoptosis in cultured astrocytes [137] or in B
lymphocytes [138]via PPARγ. 15d-PGJ2 can also trigger
the apoptosis of endothelial cells via a PPAR-dependent
pathway [139]. Part of the effectiveness of the PPARγ ago-
nists troglitazone and 15d-PGJ2 in the rat adjuvant arthri-
tis model of human rheumatoid arthritis is via inducing
apoptosis in synoviocytes [140]. PPARγ ligands also in-
duce apoptosis in human hepatocellular and esophageal
carcinoma cells [134,141].
The mechanism underlying the induction of apoptosis is
not clear, but evidence suggests that TZDs could interfere
with the anti-apoptotic NFκB signaling pathway. The in-
duction of apoptosis by PPARγ is increased by costimula-
tion with TNFα-related apoptosis-inducing ligand
(TRAIL), a member of the TNF family [142]. It has not
been determined whether a similar NFκB inhibition
might be responsible for the observed TRAIL-induced pro-
apoptotic effects of TZDs, which enhances apoptosis in tu-
mor cells. To date, no reports are available on ligand-in-
duced apoptosis in liver with high PPARγ expression
levels.
The inhibition of cell growth observed in human breast
cancer cells treated in vitro with ligands for PPARγ and
retinoic acid receptor is accompanied with a profound de-
crease of Bcl-2 gene expression and a marked increase in
apoptosis [143]. Troglitazone induced apoptosis in six
HCC by caspase-dependent (mitochondrial transmem-
brane potential decrease, cleavage of poly [adenosine di-
phosphate ribose] polymerase, 7A6 antigen exposure, Bcl-
2 decrease, and activation of caspase 3) and caspase-inde-
pendent (phosphatidylserine externalization) mecha-
nisms [134].
PPARβ
Role of PPARβ activation on mitosis
PPARβ was identified as a downstream target gene for
APC/β-catenin/T cell factor-4 (TCF-4) tumor suppressor
pathway, which is involved in the regulation of growth
promoting genes such as c-myc and cyclin D1. Indeed,
PPARβ expression was elevated in human colorectal can-
cer cells and was down-regulated upon restoration of APC
expression in these cells [144]. This down-regulation ap-
peared to be direct as the promoter of PPARβ contains β-
catenin/TCF-4-responsive elements, and PPARβ promoter
reporters were repressed by APC as well as stimulated by
mutants of β-catenin (resistant to the inhibitory effect of
APC). Genetic disruption of PPARβ also decreased the tu-
morigenicity of human colon cancer cells transplanted in
mice, thus suggesting that PPARβ contributes to the
growth-inhibitory properties of the APC tumor suppressor
[145]. In other experiments with vascular tissues, PPARβ
was found up-regulated during vascular lesion formation
and promoted post-confluent cell proliferation in vascu-
lar smooth muscle cells (VSMC) by increasing the cyclin A
and CDK2 as well as decreasing p57kip2 [146].
Role of PPARβ activation on apoptosis
PPARβ plays an antiapoptotic role in keratinocytes via
transcriptional control of the Akt1 signaling pathway
[147]. Both 3-phosphoinositide-dependent kinase-1 and
integrin-linked kinase are target genes of PPARβ. The up-
regulation of these genes together with the down-regula-
tion of PTEN led to an increase of Akt1 activity in kerati-
nocytes and suppressed apoptosis induced by growth
factors deprivation in cell culture.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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Relevance to human health
Cancer
Role of PPARα
Although rodents are sensitive to the hepatocarcinogenic
effects of PP, there is little evidence that humans are at in-
creased risk of liver cancer, even after chronic exposure.
The hypolipidemic drugs gemfibrozil and clofibrate have
been used in the clinic for 15 and 30 years, respectively,
and epidemiological studies do not reveal a statistically
significant increase in cancer up to 8 years after initiation
of therapy [148]. Livers from humans and monkeys given
fibrate drugs showed no evidence of peroxisome prolifer-
ation [149–152]. Human and marmoset hepatocyte cul-
tures, in contrast to rats, are unresponsive to treatment to
MEHP [153].
There are several possibilities that could account for lack
of peroxisome proliferation in human liver compared to
rats and mice. Even though functionally active, the hu-
man PPARα is expressed at only about 10% of that in
mouse liver [154], and extracts from human liver contain
little PPARα that can bind to PPRE [155]. Recently, mu-
tant forms have been described in some human liver sam-
ples: hPPARα8/14 is a truncated receptor that results from
aberrant splicing of the PPARα mRNA [154]; hPPARα6/
29 is a full length receptor that binds to PPRE, yet cannot
be activated by PPs [113]. However, screening of a sample
of the human population for the presence of hPPARα6/29
revealed that this form is rare. An alteration of the PPRE
sequence in the human acyl-CoA oxidase gene might also
explain the relative human unresponsiveness to PPARα
ligands [156]. Finally, species-specific responses to some
synthetic PPARα ligands, as analyzed in Xenopus, mouse
and human PPARα have also been observed [157,158].
These dramatic differences in PPARα expression and activ-
ity or in PPRE structure may account for the absence of in-
dicators of PP response in human liver, including
peroxisome proliferation and cell proliferation/apoptosis
suppression [148]. Different levels of expression of PPA-
Rα may have differential effects on gene expression. The
PPARα activity induced by these drugs in humans could
be sufficient to mediate hypolipidaemia but too low to
trigger transcriptional induction of genes involved in per-
oxisome proliferation and adverse effects [159]. As well as
being resistant to peroxisome proliferation, human hepa-
tocytes are also resistant to PP-mediated induction of mi-
tosis and suppression of apoptosis [148,160]. Because the
rodent hepatocarcinogenesis following PP exposure is
mediated by PPARα, the current evidence suggests that
humans exposed to these compounds are not likely to de-
velop liver tumors.
Anecdotically, PPARα agonists have been reported to sup-
press the growth of a human hepatoma cell line [161]. A
massive apoptosis was observed in the AH-130 hepatoma,
a poorly differentiated tumor, maintained by weekly
transplantations in rats, upon exposure to clofibrate. Sim-
ilar results were obtained with HepG2 cells. The mecha-
nisms by which clofibrate induces apoptosis are still
unclear. Since the peroxisome proliferator-activated re-
ceptor was expressed at a very low level and was not stim-
ulated by clofibrate in the AH-130 hepatoma cells, its
involvement seems unlikely. Phospholipids and choles-
terol were significantly decreased, suggesting an inhibi-
tion of the mevalonate pathway and, therefore, of
isoprenylation of proteins involved in cell proliferation.
Role of PPARγ
Recent evidence suggests that PPARγ ligands could have
an anti-tumor effect in humans as these compounds de-
crease cell growth and induce apoptosis in several malig-
nant human cell types, including HCC [134], breast
adenocarcinoma [124,143] and colon adenocarcinoma
[125]. In addition, loss-of-function mutations in PPARγ
were identified in a subset of human colorectal tumors,
supporting a role for PPARγ as a tumor suppressor of
colorectal carcinogenesis [162]. In agreement with a po-
tential role of PPARγ ligands for the treatment of cancer,
troglitazone treatment was found active in the treatment
of advanced liposarcoma [163]. On the other hand, al-
though some recent findings have suggested a potentially
important use for PPARγ ligands as chemo-preventative
agents in colon cancer [133], the PPARγ ligand troglita-
zone was not found active in the treatment of metastatic
colorectal cancer during a phase II clinical trial [164]. The
potential beneficial effect of PPARγ ligands in the treat-
ment of human HCC has not yet been tested.
Role of PPARβ
A link exists between PPARβ and human cancer via the
APC tumor repressor gene. In the majority of human
colorectal cancers, APC is inactivated by deletions, thus
giving rise to increased levels of β-catenin/TCF-4 mediated
transcriptional activity. PPARβ is, beside c-myc and cyclin
D1, one of the target genes regulated by this transcription
complex and thus may contribute to cell proliferation in
cancer. Epidemiological studies have shown a decrease
risk of colorectal carcinoma deaths associated with the use
of the non-steroidal anti-inflammatory drug (NSAID) as-
pirin. Moreover, in individuals with familial adenoma-
tous polyposis, an inherited predisposition to multiple
colorectal polyps, the NSAID sulindac can reduce both the
size and the number of colorectal tumors. Interestingly,
sulindac was shown to bind and antagonize PPARβ lead-
ing to increased apoptosis in colon cancer cells [144].
Thus PPARβ may be a critical intermediate in the tumori-
genesis pathway of the APC gene and may be a molecular
target of the effect of NSAID in colorectal cancer.Comparative Hepatology 2003, 2 http://www.comparative-hepatology.com/content/2/1/3
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Hepatic toxicity induced by the PPARγ agonist 
troglitazone
Troglitazone is an antidiabetic agent, which has been re-
ported to cause severe hepatic injury in certain individu-
als. The mechanism underlying this rare but severe
adverse drug reaction associated with troglitazone is not
clear. Results obtained with HepG2 cells suggest that tro-
glitazone induces apoptotic hepatocyte death, which may
be one of the factors of liver injury in humans [165]. As
hepatocytes in some diabetes type II patients contain
higher level of PPARγ level, this could be related to an in-
creased risk of troglitazone-induced hepatotoxicity in
these patients [166].
Other pathologies
PPARγ agonists have been proposed as therapeutic targets
against inflammation and atherosclerosis in humans.
Indeed, PPARγ agonists, which decrease cytokine secre-
tion as TNFα, IL-1, IL-6 in macrophages, and which in-
crease apoptosis in macrophages and synoviocytes [140],
could potentially be used to treat rheumatoid arthritis
[167]. PPARγ agonists, which protect against the prolifer-
ation of vascular smooth muscle cells after vascular injury
in animal models may have a similar effect in humans
[121].
Conclusions
The regulation of apoptosis and mitosis by PPAR ligands
in rodent models is complex but much has been done in
the last 10 years towards understanding the pathways in-
volved. For the rodent liver, the mode of action of PPARα
ligands is understood sufficiently to permit us to conclude
that this is not relevant to humans. However, the genes
that are activated by PPARα ligands to regulate apoptosis
and mitosis remain to be determined.
For other modes of action, the pathways are less clear, lim-
iting the usefulness of rodent models of clinical toxicity.
However, the advent of new technologies such as pro-
teomics, genomics and pharmacogenetics is allowing
more innovative approaches to these difficult issues.
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